Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings, Inc., commonly known as Zimmer Biomet, is a publicly traded American medical device company headquartered in Warsaw, Indiana. Founded in 1927, it trades on the New York Stock Exchange under the ticker symbol ZBH and is a component of the S&P 500. The company is a significant player in its industry, reporting approximately 17,000 employees as of 2024 and annual revenues of approximately $8.40 billion (TTM 2026). Its market capitalization is around $17.8 billion to $18.8 billion.

Zimmer Biomet is a global leader in musculoskeletal healthcare, specializing in the design, manufacture, and marketing of a comprehensive suite of orthopedic products. Its offerings include reconstructive products for knees, hips, shoulders, elbows, feet, and ankles, as well as dental implants, sports medicine products, biologics, and solutions for extremities and trauma. The company also develops and integrates digital and robotic technologies, such as the ROSA Robotics platform and the ZBEdge Connected Intelligence Suite, to support surgical procedures and patient care.

In terms of patent litigation, Zimmer Biomet exhibits characteristics of an active two-way litigant. The company has been involved in two tracked cases, appearing once as a plaintiff and once as a defendant. As a plaintiff, Zimmer Biomet is involved in Embody Inc. et al. v. LifeNet Health at the United States Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB). Concurrently, it is a defendant in LifeNet Health v. Zimmer Biomet Holdings Inc. et al. in the Virginia Eastern District Court.

A notable context surrounding its litigation is Zimmer Biomet's intention to acquire Embody, Inc. in January 2023. This acquisition likely links to the Embody Inc. et al. v. LifeNet Health case, suggesting the suit may involve intellectual property either related to Embody's technology or a shared interest with LifeNet Health.